PDB Short entry for 1EAS HEADER HYDROLASE (SERINE PROTEASE) 22-NOV-94 1EAS TITLE NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 3. DESIGN, TITLE 2 SYNTHESIS, X-RAY CRYSTALLOGRAPHIC ANALYSIS, AND STRUCTURE-ACTIVITY TITLE 3 RELATIONSHIPS FOR A SERIES OF ORALLY ACTIVE 3-AMINO-6-PHENYLPYRIDIN- TITLE 4 2-ONE TRIFLUOROMETHYL KETONES COMPND MOL_ID: 1; COMPND 2 MOLECULE: PORCINE PANCREATIC ELASTASE; COMPND 3 CHAIN: A; COMPND 4 EC: 3.4.21.36; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SUS SCROFA; SOURCE 3 ORGANISM_COMMON: PIG; SOURCE 4 ORGANISM_TAXID: 9823 KEYWDS HYDROLASE (SERINE PROTEASE) EXPDTA X-RAY DIFFRACTION AUTHOR C.CECCARELLI REVDAT 4 22-FEB-12 1EAS 1 JRNL VERSN REVDAT 3 24-FEB-09 1EAS 1 VERSN REVDAT 2 01-APR-03 1EAS 1 JRNL REVDAT 1 07-FEB-95 1EAS 0 JRNL AUTH P.R.BERNSTEIN,D.ANDISIK,P.K.BRADLEY,C.B.BRYANT,C.CECCARELLI, JRNL AUTH 2 J.R.DAMEWOOD JR.,R.EARLEY,P.D.EDWARDS,S.FEENEY,B.C.GOMES, JRNL AUTH 3 B.J.KOSMIDER,G.B.STEELMAN,R.M.THOMAS,E.P.VACEK,C.A.VEALE, JRNL AUTH 4 J.C.WILLIAMS,D.J.WOLANIN,J.A.WOOLSON JRNL TITL NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 3. JRNL TITL 2 DESIGN, SYNTHESIS, X-RAY CRYSTALLOGRAPHIC ANALYSIS, AND JRNL TITL 3 STRUCTURE-ACTIVITY RELATIONSHIPS FOR A SERIES OF ORALLY JRNL TITL 4 ACTIVE 3-AMINO-6-PHENYLPYRIDIN-2-ONE TRIFLUOROMETHYL JRNL TITL 5 KETONES. JRNL REF J.MED.CHEM. V. 37 3313 1994 JRNL REFN ISSN 0022-2623 JRNL PMID 7932559 JRNL DOI 10.1021/JM00046A016 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH P.R.BERNSTEIN,B.C.GOMES,B.J.KOSMIDER,E.P.VACEK,J.C.WILLIAMS REMARK 1 TITL NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 6. REMARK 1 TITL 2 DESIGN OF A POTENT, INTRATRACHEALLY ACTIVE, PYRIDONE-BASED REMARK 1 TITL 3 TRIFLUOROMETHYL KETONE REMARK 1 REF TO BE PUBLISHED REMARK 1 REFN REMARK 1 REFERENCE 2 REMARK 1 AUTH C.A.VEALE,P.R.BERNSTEIN,C.BRYANT,C.CECCARELLI,J.R.DAMEWOOD, REMARK 1 AUTH 2 R.EARLEY,S.W.FEENEY,B.GOMES,B.J.KOSMIDER,G.B.STEELMAN, REMARK 1 AUTH 3 R.M.THOMAS,E.P.VACEK,J.C.WILLIAMS,D.J.WOLANIN,S.WOOLSON REMARK 1 TITL NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 5. REMARK 1 TITL 2 DESIGN, SYNTHESIS, AND X-RAY CRYSTALLOGRAPHY OF A SERIES OF REMARK 1 TITL 3 ORALLY ACTIVE 5-AMINO-PYRIMIDIN-6-ONE-CONTAINING REMARK 1 TITL 4 TRIFLUOROMETHYLKETONES REMARK 1 REF TO BE PUBLISHED REMARK 1 REFN REMARK 1 REFERENCE 3 REMARK 1 AUTH C.A.VEALE,J.R.DAMEWOOD,G.B.STEELMAN,C.BRYANT,B.GOMES, REMARK 1 AUTH 2 J.WILLIAMS REMARK 1 TITL NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 4. REMARK 1 TITL 2 DESIGN, SYNTHESIS,IN VITRO, AND IN VIVO ACTIVITY OF A SERIES REMARK 1 TITL 3 OF BETA-CARBOLINONE-CONTAINING TRIFLUOROMETHYL KETONES REMARK 1 REF TO BE PUBLISHED REMARK 1 REFN REMARK 1 REFERENCE 4 REMARK 1 AUTH J.R.DAMEWOOD,P.D.EDWARDS,S.FEENEY,B.C.GOMES,G.B.STEELMAN, REMARK 1 AUTH 2 P.A.TUTHILL,P.WARNER,J.C.WILLIAMS,S.A.WOOLSON,D.WOLANIN, REMARK 1 AUTH 3 C.VEALE REMARK 1 TITL NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 2. REMARK 1 TITL 2 DESIGN, SYNTHESIS AND IN VITRO ACTIVITY OF A SERIES OF REMARK 1 TITL 3 3-AMINO-6-ARYLPYRIDIN-2-ONE TRIFLUOROMETHYL KETONES REMARK 1 REF J.MED.CHEM. V. 37 3303 1994 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 5 REMARK 1 AUTH P.WARNER,R.C.GREEN,B.C.GOMES,J.C.WILLIAMS REMARK 1 TITL NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 1. THE REMARK 1 TITL 2 DESIGN AND SYNTHESIS OF PYRIDONE-CONTAINING INHIBITORS REMARK 1 REF J.MED.CHEM. V. 37 3090 1994 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 6 REMARK 1 AUTH F.J.BROWN,D.W.ANDISIK,P.R.BERNSTEIN,C.B.BRYANT,C.CECCARELLI, REMARK 1 AUTH 2 J.R.DAMEWOOD,P.D.EDWARDS,R.EARLEY,S.W.FEENEY,R.C.GREEN, REMARK 1 AUTH 3 B.GOMES,B.J.KOSMIDER,R.KRELL,A.SHAW,G.B.STEELMAN,R.M.THOMAS, REMARK 1 AUTH 4 E.P.VACEK,C.A.VEALE,P.A.TUTHILL,P.WARNER,J.C.WILLIAMS, REMARK 1 AUTH 5 D.J.WOLANIN,S.A.WOOLSON REMARK 1 TITL DESIGN OF ORALLY ACTIVE, NONPEPTIDIC INHIBITORS OF HUMAN REMARK 1 TITL 2 LEUKOCYTE ELASTASE REMARK 1 REF J.MED.CHEM. V. 37 1259 1994 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 7 REMARK 1 AUTH P.D.EDWARDS,E.F.MEYER,J.VIJAYALAKSHMI,P.A.TUTHILL, REMARK 1 AUTH 2 D.A.ANDISIK,B.GOMES,A.STRIMPLER REMARK 1 TITL DESIGN, SYNTHESIS, AND KINETIC EVALUATION OF A UNIQUE CLASS REMARK 1 TITL 2 OF ELASTASE INHIBITORS, THE PEPTIDYL REMARK 1 TITL 3 ALPHA-KETOBENZOXAZOLES,AND THE X-RAY CRYSTAL STRUCTURE OF REMARK 1 TITL 4 THE COVALENT COMPLEX BETWEEN PORCINE PANCREATIC ELASTASE AND REMARK 1 TITL 5 AC-ALA-PRO-VAL-2-BENZOXAZOLE REMARK 1 REF J.AM.CHEM.SOC. V. 114 1854 1992 REMARK 1 REFN ISSN 0002-7863 REMARK 1 REFERENCE 8 REMARK 1 AUTH L.H.TAKAHASHI,R.RADHAKRISHNAN,R.E.ROSENFIELD,E.F.MEYER, REMARK 1 AUTH 2 D.A.TRAINOR REMARK 1 TITL CRYSTAL STRUCTURE OF THE COVALENT COMPLEX FORMED BY A REMARK 1 TITL 2 PEPTIDYL ALPHA,ALPHA-DIFLUORO-BETA-KETO AMIDE WITH PORCINE REMARK 1 TITL 3 PANCREATIC ELASTASE AT 1.78-ANGSTROM RESOLUTION REMARK 1 REF J.AM.CHEM.SOC. V. 111 3368 1989 REMARK 1 REFN ISSN 0002-7863 REMARK 1 REFERENCE 9 REMARK 1 AUTH L.H.TAKAHASHI,R.RADHAKRISHNAN,R.E.ROSENFIELD,E.F.MEYER, REMARK 1 AUTH 2 D.A.TRAINOR,M.STEIN REMARK 1 TITL X-RAY DIFFRACTION ANALYSIS OF THE INHIBITION OF PORCINE REMARK 1 TITL 2 PANCREATIC ELASTASE BY A PEPTIDYL TRIFLUOROMETHYLKETONE REMARK 1 REF J.MOL.BIOL. V. 201 423 1988 REMARK 1 REFN ISSN 0022-2836 REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 88.0 REMARK 3 NUMBER OF REFLECTIONS : 19022 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING SET) : 0.183 REMARK 3 FREE R VALUE : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1822 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 49 REMARK 3 SOLVENT ATOMS : 124 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 19.70 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.20 REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.62 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 26.30 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.38 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1EAS COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : NULL REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : NULL REMARK 200 RADIATION SOURCE : NULL REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : NULL REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19195 REMARK 200 RESOLUTION RANGE HIGH (A) : NULL REMARK 200 RESOLUTION RANGE LOW (A) : NULL REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 88.0 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 43.69 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.18 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.97500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 37.78000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.86500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 37.78000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.97500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 28.86500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 36 NE - CZ - NH2 ANGL. DEV. = -3.1 DEGREES REMARK 500 ASP A 98 N - CA - C ANGL. DEV. = 22.6 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 HIS A 71 -50.42 -130.42 REMARK 500 ASP A 98 79.82 -52.01 REMARK 500 ASN A 115 -158.23 -158.79 REMARK 500 TYR A 171 -109.28 -115.29 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CHIRAL CENTERS REMARK 500 REMARK 500 UNEXPECTED CONFIGURATION OF THE FOLLOWING CHIRAL REMARK 500 CENTER(S) USING IMPROPER CA--C--CB--N CHIRALITY REMARK 500 FOR AMINO ACIDS AND C1'--O4'--N1(N9)--C2' FOR REMARK 500 NUCLEIC ACIDS OR EQUIVALENT ANGLE REMARK 500 M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,6X,F5.1,6X,A1,10X,A1,3X,A16) REMARK 500 REMARK 500 M RES CSSEQI IMPROPER EXPECTED FOUND DETAILS REMARK 500 ASP A 98 20.5 L L OUTSIDE RANGE REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 C2 OF HET GROUP TFK IS COVALENTLY BONDED TO O-GAMMA OF REMARK 600 SER 195. REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA A 5 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASN A 72 O REMARK 620 2 HOH A 318 O 106.7 REMARK 620 3 GLN A 75 O 78.1 71.8 REMARK 620 4 ASN A 77 OD1 86.0 164.7 103.4 REMARK 620 5 GLU A 80 OE2 163.6 88.4 101.2 78.2 REMARK 620 6 GLU A 70 OE1 97.6 95.6 164.5 91.0 87.1 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: CAT REMARK 800 EVIDENCE_CODE: UNKNOWN REMARK 800 SITE_DESCRIPTION: NULL REMARK 800 REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA A 5 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 2 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 3 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 4 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE TFK A 1 DBREF 1EAS A 16 245 UNP P00772 ELA1_PIG 27 266 SEQADV 1EAS ASN A 77 UNP P00772 ASP 92 CONFLICT SEQRES 1 A 240 VAL VAL GLY GLY THR GLU ALA GLN ARG ASN SER TRP PRO SEQRES 2 A 240 SER GLN ILE SER LEU GLN TYR ARG SER GLY SER SER TRP SEQRES 3 A 240 ALA HIS THR CYS GLY GLY THR LEU ILE ARG GLN ASN TRP SEQRES 4 A 240 VAL MET THR ALA ALA HIS CYS VAL ASP ARG GLU LEU THR SEQRES 5 A 240 PHE ARG VAL VAL VAL GLY GLU HIS ASN LEU ASN GLN ASN SEQRES 6 A 240 ASN GLY THR GLU GLN TYR VAL GLY VAL GLN LYS ILE VAL SEQRES 7 A 240 VAL HIS PRO TYR TRP ASN THR ASP ASP VAL ALA ALA GLY SEQRES 8 A 240 TYR ASP ILE ALA LEU LEU ARG LEU ALA GLN SER VAL THR SEQRES 9 A 240 LEU ASN SER TYR VAL GLN LEU GLY VAL LEU PRO ARG ALA SEQRES 10 A 240 GLY THR ILE LEU ALA ASN ASN SER PRO CYS TYR ILE THR SEQRES 11 A 240 GLY TRP GLY LEU THR ARG THR ASN GLY GLN LEU ALA GLN SEQRES 12 A 240 THR LEU GLN GLN ALA TYR LEU PRO THR VAL ASP TYR ALA SEQRES 13 A 240 ILE CYS SER SER SER SER TYR TRP GLY SER THR VAL LYS SEQRES 14 A 240 ASN SER MET VAL CYS ALA GLY GLY ASP GLY VAL ARG SER SEQRES 15 A 240 GLY CYS GLN GLY ASP SER GLY GLY PRO LEU HIS CYS LEU SEQRES 16 A 240 VAL ASN GLY GLN TYR ALA VAL HIS GLY VAL THR SER PHE SEQRES 17 A 240 VAL SER ARG LEU GLY CYS ASN VAL THR ARG LYS PRO THR SEQRES 18 A 240 VAL PHE THR ARG VAL SER ALA TYR ILE SER TRP ILE ASN SEQRES 19 A 240 ASN VAL ILE ALA SER ASN HET NA A 5 1 HET SO4 A 2 5 HET SO4 A 3 5 HET SO4 A 4 5 HET TFK A 1 33 HETNAM NA SODIUM ION HETNAM SO4 SULFATE ION HETNAM TFK 3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3, HETNAM 2 TFK 3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)- HETNAM 3 TFK PYRIDINE ACETAMIDE FORMUL 2 NA NA 1+ FORMUL 3 SO4 3(O4 S 2-) FORMUL 6 TFK C20 H23 F3 N4 O5 S FORMUL 7 HOH *124(H2 O) HELIX 1 1 ALA A 55 VAL A 59 5 5 HELIX 2 2 ASP A 164 SER A 169 1 6 HELIX 3 3 TRP A 172 VAL A 176 5 5 HELIX 4 4 TYR A 234 ASN A 245 1 12 SHEET 1 A 8 THR A 20 GLU A 21 0 SHEET 2 A 8 GLN A 156 TYR A 159 -1 N GLN A 157 O THR A 20 SHEET 3 A 8 CYS A 136 GLY A 140 -1 N ILE A 138 O ALA A 158 SHEET 4 A 8 PRO A 198 VAL A 203 -1 O PRO A 198 N THR A 139 SHEET 5 A 8 GLN A 206 PHE A 215 -1 O GLN A 206 N VAL A 203 SHEET 6 A 8 THR A 226 ARG A 230 -1 N VAL A 227 O PHE A 215 SHEET 7 A 8 MET A 180 ALA A 183 -1 O VAL A 181 N PHE A 228 SHEET 8 A 8 THR A 162 VAL A 163 -1 N VAL A 163 O CYS A 182 SHEET 1 B 7 SER A 37 ARG A 48 0 SHEET 2 B 7 TRP A 51 THR A 54 -1 O TRP A 51 N ILE A 47 SHEET 3 B 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 4 B 7 GLN A 81 VAL A 90 -1 N GLN A 86 O ARG A 107 SHEET 5 B 7 PHE A 65 VAL A 68 -1 O PHE A 65 N VAL A 85 SSBOND 1 CYS A 42 CYS A 58 1555 1555 2.03 SSBOND 2 CYS A 136 CYS A 201 1555 1555 2.03 SSBOND 3 CYS A 168 CYS A 182 1555 1555 2.03 SSBOND 4 CYS A 191 CYS A 220 1555 1555 2.02 LINK C2 TFK A 1 OG SER A 195 1555 1555 1.45 LINK NA NA A 5 O ASN A 72 1555 1555 2.36 LINK NA NA A 5 O HOH A 318 1555 1555 2.37 LINK NA NA A 5 O GLN A 75 1555 1555 2.36 LINK NA NA A 5 OD1 ASN A 77 1555 1555 2.48 LINK NA NA A 5 OE2 GLU A 80 1555 1555 2.56 LINK NA NA A 5 OE1 GLU A 70 1555 1555 2.47 SITE 1 CAT 4 HIS A 57 ASP A 102 SER A 195 SER A 214 SITE 1 AC1 6 GLU A 70 ASN A 72 GLN A 75 ASN A 77 SITE 2 AC1 6 GLU A 80 HOH A 318 SITE 1 AC2 6 GLY A 127 ARG A 145 ARG A 230 SER A 232 SITE 2 AC2 6 ALA A 233 HOH A 289 SITE 1 AC3 7 ARG A 36 GLY A 36B THR A 64 ALA A 99A SITE 2 AC3 7 SER A 174 THR A 175 LYS A 177 SITE 1 AC4 5 TFK A 1 VAL A 85 ILE A 88 HOH A 272 SITE 2 AC4 5 HOH A 344 SITE 1 AC5 17 SO4 A 4 CYS A 42 HIS A 57 GLU A 62 SITE 2 AC5 17 CYS A 191 GLN A 192 GLY A 193 ASP A 194 SITE 3 AC5 17 SER A 195 THR A 213 SER A 214 PHE A 215 SITE 4 AC5 17 VAL A 216 SER A 217 ARG A 217A HOH A 339 SITE 5 AC5 17 HOH A 344 CRYST1 51.950 57.730 75.560 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019249 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017322 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013235 0.00000